Citable filing context
BSX's research view summarizes recent SEC filing context, starting with management_change from Sep 23, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 23, 2026 | management_change | Arthur C. Butcher, Executive Vice President and Group President, announced his retirement effective January 1, 2027. |
| Sep 8, 2026 | other | Boston Scientific reported an operational update on a cybersecurity incident, stating it will likely miss 2026 financial guidance. |
| Aug 26, 2026 | other | Boston Scientific reported a cybersecurity incident identified on August 25, 2026, causing global operational disruptions. |
| Jul 29, 2026 | Guidance: adjusted_eps | 3.28 to 3.32 |
| Jul 29, 2026 | Guidance: adjusted_eps | 0.80 to 0.82 |
| Jul 29, 2026 | Guidance: organic_net_sales_growth | 5.00 to 6.00 |
| Aug 3, 2026 | mda_quarterly | Boston Scientific reported strong financial performance for the first half of 2026, with net sales reaching $10.65 billion, a 9.5% increase over the prior year. Growth was primarily driven by the Cardiovascular segment, specifically the Farapulse Pulsed Field Ablation system and the AGENT drug-coated balloon, alongside the Endoscopy business. The company’s operating income rose to $2.28 billion, bolstered by higher sales volumes and improved gross margins, which reached 70.1% for the six-month period. Strategic expansion remains a priority, with the company currently awaiting regulatory clearance for the $14.5 billion acquisition of Penumbra, Inc., which will be integrated into the Cardiovascular division. Additionally, Boston Scientific invested $1.6 billion in MiRus LLC, securing an exclusive option to acquire its TAVR structural heart business. To support long-term efficiency, the company initiated a new global restructuring program in July 2026, expected to incur $700–$800 million in pre-tax charges through 2029. Key risks include ongoing litigation, such as the recently consolidated Multi-District Litigation regarding spinal cord stimulation products, and potential macroeconomic volatility, including trade policy shifts and tariff impacts. The company maintains a solid liquidity position, supported by new credit agreements and a $5 billion share repurchase authorization, of which $3 billion remains available. |
| May 1, 2026 | mda_quarterly | Boston Scientific reported first-quarter 2026 net sales of $5.2 billion, an 11.6% increase, with 9.4% organic growth. Reported net income rose to $1.34 billion, bolstered by higher sales and a $384 million discrete tax benefit. The Cardiovascular segment led performance with 13.5% growth, driven by the Farapulse Pulsed Field Ablation System, WATCHMAN Left Atrial Appendage Closure Devices, and AGENT Drug-Coated Balloons, despite increased competition and a deceleration in WATCHMAN procedures. Neuromodulation grew 17.4%, led by the Intracept Intraosseous Nerve Ablation and Nalu Peripheral Nerve Stimulation systems. In contrast, Urology growth was constrained to 2.1% by volume-based procurement in China and sacral neuromodulation commercial disruptions. Gross margin improved to 69.4% due to a higher-margin product mix. A significant strategic focus is the $14.5 billion acquisition of Penumbra, which is currently subject to an FTC Second Request. The company maintains a strong liquidity position with $1.45 billion in cash and a 1.87x leverage ratio, well within its 4.25x covenant. Management remains cautious regarding macroeconomic risks, specifically global trade policy uncertainty, tariff volatility, and potential supply chain disruptions. |
Source: SEC EDGAR filing text and events; period Sep 23, 2026; filed Sep 23, 2026.
BSX company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.